Gsk (GSK) Net Income towards Common Stockholders Growth (1y) (2010 - 2026)
Gsk (GSK) Net Income towards Common Stockholders Growth (1y) (2010 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
Net Income Growth (1y) (Qtr) |
| 1 |
Gsk |
96,436,181.12 Bn |
96,436,176.16 Bn |
7.76 Bn |
14.49% |
| 2 |
Eli Lilly |
1,017.30 Bn |
1,012.01 Bn |
16.22 Bn |
168.07% |
| 3 |
Johnson & Johnson |
579.61 Bn |
557.55 Bn |
15.96 Bn |
-52.40% |
| 4 |
AbbVie |
402.30 Bn |
392.96 Bn |
10.78 Bn |
-45.93% |
| 5 |
Merck |
294.24 Bn |
288.59 Bn |
12.09 Bn |
-182.77% |
| 6 |
Amgen |
191.82 Bn |
179.78 Bn |
5.87 Bn |
5.14% |
| 7 |
Gilead Sciences |
155.93 Bn |
148.21 Bn |
5.52 Bn |
53.69% |
| 8 |
Pfizer |
149.05 Bn |
136.28 Bn |
-1.21 Bn |
- |
| 9 |
Bristol Myers Squibb |
116.33 Bn |
105.88 Bn |
8.07 Bn |
8.81% |
| 10 |
Novartis Ag |
112.59 Bn |
111.90 Bn |
- |
- |
| Date | Value |
|---|
| Mar 31, 2026 |
14.49% |
| Dec 31, 2025 |
-70.30% |
| Sep 30, 2025 |
3,704.42% |
| Jun 30, 2025 |
30.02% |
| Mar 31, 2025 |
54.15% |
| Dec 31, 2024 |
-26.31% |
| Sep 30, 2024 |
-104.06% |
| Jun 30, 2024 |
-27.14% |
| Mar 31, 2024 |
-26.74% |
| Dec 31, 2023 |
-77.97% |
| Sep 30, 2023 |
-85.46% |
| Jun 30, 2023 |
92.57% |
| Mar 31, 2023 |
-25.10% |
| Dec 31, 2022 |
1,637.45% |
| Sep 30, 2022 |
692.03% |
| Jun 30, 2022 |
-45.88% |
| Mar 31, 2022 |
63.42% |
| Dec 31, 2021 |
-86.70% |
| Sep 30, 2021 |
-66.78% |
| Jun 30, 2021 |
-30.61% |
